Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRE11 | P49959 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 11/20 | 0.38 |
| ▸ | GIPR | P48546 | 9/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | STAT5B | P51692 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999217 | 0.91 | STAT3 (0.39) | MRE11S1PR1S1PR5S1PR3TRPA1 | |
| SCHEMBL5999147 | 0.90 | GCGR (0.40) | MRE11GCGRGIPRS1PR1S1PR5 | |
| SCHEMBL5999733 | 0.88 | RXRA (0.42) | MRE11S1PR1TRPA1STAT3STAT1 | |
| SCHEMBL6001059 | 0.86 | RXRA (0.42) | MRE11S1PR1TRPA1STAT3STAT1 | |
| SCHEMBL6000692 | 0.85 | MRE11 (0.40) | MRE11GCGRGIPRS1PR1S1PR5 | |
| SCHEMBL6000148 | 0.85 | NPC1 (0.41) | MRE11GCGRGIPRS1PR1S1PR5 | |
| SCHEMBL6000602 | 0.85 | STAT3 (0.41) | MRE11GCGRGIPRTRPA1STAT3 | |
| SCHEMBL6000047 | 0.84 | STAT3 (0.41) | MRE11STAT3STAT1STAT5B | |
| SCHEMBL6000063 | 0.84 | MRE11 (0.40) | MRE11GCGRGIPRS1PR1S1PR5 | |
| SCHEMBL5999919 | 0.84 | PTPN2 (0.40) | MRE11TRPA1STAT3STAT1STAT5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | MRE11 4881/4885GCGR 194/4885GIPR 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.